Glucosamine

To evaluate the efficacy and safety of chondroitin sulfate and/or glucosamine hydrochloride in alleviating symptoms and improving the dysfunction of Kashin-Beck disease (KBD) patients.

Purpose: SYSADOAs (symptomatic slow-acting drugs for osteoarthritis) are a heterogeneous group of drugs that have the ability to modify the symptoms of osteoarthritis (OA) slowly and independently of NSAIDs, analgesics or any other therapeutic option. The main drugs included in this group are glucosamine (sulphate or hydrochloride) (GS) and chondroitin sulphate (CS), widely prescribed for the treatment of OA in some countries. Although the efficacy of GS and CS for the treatment of OA remains controversial, several human, animal and laboratory studies have suggested that both drugs show anti-inflammatory properties that could reduce the risk of several diseases.

Background To investigate the ameliorative effects of glucosamine (GS), chondroitin sulphate (CS) and glucosamine plus chondroitin sulphate (GC) on rheumatoid arthritis (RA) in rats, and to explore the mechanism of GS, CS and GC in improving RA based on the gut microbiota. Methods RA rat models were effectively developed 14 days after CFA injection, and then garaged with GS, CS and GC. Body weight and paw volume of rats were monitored at multiple time points at the beginning of CFA injection. Until D36, serum and ankle tissue specimens were used to measure levels of circulating inflammatory factors (TNF-α, IL-1β, MMP-3, NO and PGE2) and local inflammatory indicators (TLR-4 and NF-κB). On D18, D25, and D36, intergroup gut microbiota was compared using 16S rRNA gene sequencing and bioinformatics analysis. We also performed the correlation analysis of gut bacteria, joint swelling and inflammatory indicators. Results GC, rather than GS and CS, could reduce right paw volumes, levels of TLR-4 and NF-κB in synovial tissues. In addition, enriched genera in RA model rats screened out by LEfSe analysis could be inhibited by GC intervention, including potential LPS-producing bacteria (Enterobacter, Bacteroides, Erysipelotrichaceae_unclassified and Erysipelotrichaceae_uncultured) and some other opportunistic pathogens (Esherichia_Shigella, Nosocomiicoccus, NK4A214_group, Odoribacter, Corynebacterium and Candidatus_Saccharimonas.etc.) that positively correlated with pro-inflammatory cytokines, right paw volume, and pathology scores. Furthermore, the gut microbiota dysbiosis was observed to recover before alleviating joint swelling after interventions. Conclusions GC could inhibit potential LPS-producing bacteria and the activation of TLR-4/NF-κB pathway in RA rats, thus alleviating RA-induced joint injury.

Recognizing the composition and modulation of the microbiome, a viable therapeutic tool for multi-targeted therapy is a new strategy that has recently been explored. Glucosamine (GS) is being studied for its prebiotic potential in addition to being the most abundant and naturally occurring amino monosaccharide. The current study focuses on glucosamine’s prebiotic potential by assessing the stability of various GS concentrations (1% - 5%) in the gastrointestinal tract (GIT) and its ability to be fermented by the gut microbiota. The results showed that GS stimulated the most growth in L. acidophilus even after a longer incubation time than B. bifidum and L. acidophilus growth was concentration-dependent, with maximum growth at 3% with a simultaneous decrease in pH (5.6 - 1.7). The decrease in GS concentration with time also represented the growth of bacterial species, demonstrating the species’ utilization of GS. Furthermore, at 3%, GS also represented the prebiotic index of 1.9. In addition, the concentration of GS in various simulated GIT fluids was estimated in both fast and fed conditions to examine GS stability at various levels in the gut. The results showed that GS remained unaffected and non-digestible in all of the simulated GIT fluids (salivary, gastric, intestinal, and colonic), but there was a slight decrease in GS concentration (2.8%) in the fasted state of gastric fluid due to low pH levels (1.6). As a result, the findings are conclusive and suggest that GS possesses prebiotic properties.

Background Low back pain (LBP) is the leading cause of Years Lived with Disability worldwide.1 The number of people suffering from LBP grew more than 50% from 1990 to 2013, to 651 million.1 Chronic low back pain can often lead to depression. Data on 1 90 593 community-dwelling adults aged ≥18 years from the World Health Survey (WHS) 2002–2004 in 43 Low and middle-income countries show a strong correlation between chronic back pain and depression.2 Glucosamine-chondroitin sulfate (GCS) combination is widely used in the treatment of OA; however, there are few prospective scientific investigations of its therapeutic merits in severe LBP. Objectives To study the efficacy of GCS in the decreasing depression in patients with chronic low back pain in a large open pilot prospective observational study. Methods We enrolled patients between 40 and 65 years of age who had LBP for at least 12 weeks with a pain intensity >3 on a 0–10-point visual analogue scale (VAS) in a single-arm, open-label prospective interventional study. Major exclusion criteria were the presence of fibromyalgia, degenerative spondylolisthesis, and alcohol and/or drug abuse. All patients were treated with a combination of glucosamine hydrochloride 500 mg and chondroitin sulfate 500 mg in tablet form (Unipharm Inc.) at a dose of 1 tablet bid for the first month and then 1 tablet daily for the next two months. The primary endpoint was pain intensity (at rest and movement) as measured on a 0–10 point VAS. Depression was measured by the 13-questionnaire Beck’s Depression Inventory (BDI). There are 13 questions in this score with highest possible score of 39 (5–7 is mild depression; 8–15 moderate depression, 16 and over severe depression).3 Results A total of 8598 subjects (mean age 52.1 years, 67.3% women, mean BMI 27.4) were enrolled in the study, and formed the intent-to-treat (ITT) population. All but 95 subjects (1.1%) completed the study. Previously-reported ITT analysis with worst observation carried forward (WOCF) showed an improvement in pain at rest from mean (±SD) of 5.2±1.9 at study entry to 1.4±1.6 at 3 months (p

A randomized double‑blind placebo‑controlled clinical study was conducted to evaluate the chondroprotective action of glucosamine on healthy subjects (soccer players) without joint disorders. Collegiate soccer players (n=43) without joint disorders were randomly assigned to receive a glucosamine (2 g/day)‑containing supplement (n=22, glucosamine group) or a placebo (n=21, placebo group) for 16 weeks, and cartilage metabolism was evaluated by analyzing markers for type II collagen degradation urine C‑terminal telopeptide‑II (CTX‑II) and serum collagen type II cleavage (C2C) and synthesis urine C-terminal type II procollagen peptide (CPII). In the initial analysis of all subjects, urine CTX‑II level substantially decreased in the glucosamine group, but not in the placebo group after the intervention for 16 weeks (P=0.05). Moreover, CTX‑II level in the glucosamine group was also significantly lower than that in the placebo group at week 16 during the intervention. In the second analysis, to make the effect of the test supplement more clear, 41 subjects with less variation of exercise loading were evaluated. The results revealed that urine CTX‑II level significantly decreased in the glucosamine group (n=21), but not in the placebo group (n=20) after the intervention (P

The anti-inflammatory properties of glucosamine and chondroitin suggest that they may have potential effects in cancer prevention. We performed this meta-analysis to assess the protective function ...

Background Growing evidence has showed an association between habitual glucosamine use and type 2 diabetes (T2D). However, the effect of habitual glucosamine use on risk of dementia remains poorly understood. Our study aimed to examine the association between glucosamine use and risk of dementia and further to identify the mediating role of T2D in the association. Methods A total of 495,942 participants from UK Biobank who completed a questionnaire on habitual glucosamine use were included at baseline (2006–2010) and then followed up for incidence of dementia until 2020. Cox proportional hazard regressions were performed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident dementia. Markov multi-state models were used to explore the role of incidence of T2D during the follow-up in the association. Results Overall, 18.80% of the participants reported habitual use of glucosamine at baseline. A total of 6831 dementia events were recorded during a median follow-up of 11 years. In fully adjusted models, habitual glucosamine use was associated with a significantly lower risk of dementia (HR = 0.87, 95% CI: 0.82–0.93). Multi-state models showed that the association between glucosamine use and dementia was mediated by the incidence of T2D during the follow-up (HR of dementia without T2D: 0.92, 95% CI: 0.86–0.99; HR of post-T2D dementia: 0.79, 95% CI: 0.67–0.93). Conclusions Our findings reveal that habitual use of glucosamine supplement is associated with a lower risk of dementia, which might be explained by incidence of T2D.

Objective: The level of precursors involved in the biosynthesis of glycosaminoglycan (GAG), glucosamine synthase, and N-acetyl glucosamine (NAG), are significantly reduced in inflammatory bowel dis...

Clinical Efficacy of Glucosamine plus Sodium Hyaluronate for Osteoporosis Complicated by Knee Osteoarthritis and Its Influence on Joint Function and Bone Metabolic Markers: Background. Osteoporosis (OP) associated with knee osteoarthritis (KOA) is common in older men and postmenopausal women, and it is important to find reliable and effective treatments for this disease to improve joint function and bone metabolism in this population. Objective. To clarify the clinical efficacy of glucosamine (GlcN) plus sodium hyaluronate (SH) for OP complicated by KOA (OP + KOA) and its influence on joint function and bone metabolic markers (BMMs). Methods. Admitted from July 2019 to July 2021, 126 patients with OP + KOA were selected, including 76 cases (observation group) treated with GlcN plus SH and 50 cases (control group) given GlcN alone. The pain, joint function, BMMs, and clinical efficacy were evaluated and compared. Pain and joint function assessments employed the Visual Analogue Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) plus Lysholm Knee Scoring Scale, respectively. BMMs mainly measured bone gla protein (BGP), serum tartrate-resistant acid phosphatase variant (TRACP)-5b, type I collagen cross-linked C-telopeptide (CTX-1), and bone-specific alkaline phosphatase (BALP). Results. Higher posttreatment VAS scores were determined in observation group as compared to control group; observation group showed lower WOMAC scores of joint function and higher Lysholm scores than control group; in terms of BMMs, TRACP-5b and CTX-1 were lower while BGP and BALP were higher in observation group; the curative effect was also higher in observation group. All the above differences were statistically significant. Conclusions. GlcN plus SH has definite clinical efficacy in the treatment of OP + KOA, which can not only significantly improve patients’ joint function and bone metabolism but also relieve pain, with high clinical popularization value.

Glucosamine, an amino-polysaccharide, has been widely used for alleviating osteoarthritis. . In the present study, attempts have been made to evaluate the potential role of glucosamine, a caloric r...

Objective. To assess the application value of comprehensive rehabilitation therapy plus glucosamine hydrochloride for exercise-induced knee injuries and its effect on knee function. Methods. A total of 96 patients with an exercise-induced knee injury who were admitted to our hospital from February 2019 to February 202 were recruited and assigned at a ratio of 1 : 1 with matched general information to a control group (n = 45) or an experimental group (n = 51). Both groups of patients received comprehensive rehabilitation therapy, and the patients in the experimental group were daily given additional glucosamine hydrochloride tablets for 8 weeks. Results. The experimental group showed a higher treatment efficacy than the control group (). After the treatment, the VAS scores and C-reactive protein of the two groups showed a decline, with a lower result in the experimental group than in the control group (). The Lysholm knee scores were increased in the two groups after the treatment, and the experimental group had a higher score (). After the treatment, patients of both groups showed reduced five-times-sit-to-stand-test (FTSST) results, with a better outcome obtained in the experimental group (). Conclusion. Comprehensive rehabilitation therapy plus glucosamine hydrochloride effectively improves the clinical efficacy of exercise-induced knee joint injuries and enhances the knee joint rehabilitation of the patients.

Currently, colorectal cancer is the third most common cancer in the world. Recently, glucosamine and chondroitin have gained popularity for their beneficial effects on cancer. They have already ...

This study aimed to investigate the effect of aerobic exercise combined with glucosamine (OTL) on the apoptosis of chondrocytes of rabbit knee osteoar…

NeuroMolecular Medicine - Neuroprotective, antineuroinflammatory, and proneurogenic effects of glucosamine, a naturally occurring amino sugar, have been reported in various animal models of brain...

Our results show that GlcN supplementation in aerobically trained mice, at doses equivalent to those conventionally used in humans, increases the protein levels of mitochondrial biogenesis markers, improves motor coordination and may have a synergistic effect with exercise training on running distan …

d-Glucosamine is a protective dietary supplement or medicine for osteoarthritis of the knee, a musculoskeletal disease that leads to a significant det…

Glucosamine use, smoking and risk of incident chronic obstructive pulmonary disease: A large prospective cohort study

Osteoarthritis (OA) and osteoporosis (OP) are common among older women, especially postmenopausal women. Glucosamine (GlcN) is a common medication for OA, but it may induce insulin resistance and β-cell dysfunction, especially if ovarian hormones are lacking. Raloxifene (RLX) is a selective estrogen receptor modulator and also an OP drug. Previously, we found that estrogen could improve GlcN-induced insulin resistance in ovariectomized (OVX) rats. Here, we further hypothesized that RLX, similarly to estrogen, can ameliorate GlcN-induced insulin resistance in OVX rats. We used GlcN to induce insulin resistance in OVX rats as a model for evaluating the protective effects of RLX in vivo. We used a pancreatic β-cell line, MIN-6, to study the mechanisms underlying the effect of RLX in GlcN-induced β-cell dysfunction in vitro. Increases in fasting plasma glucose, insulin, and homeostasis model assessments of insulin resistance in OVX Sprague Dawley rats treated with GlcN were reversed by RLX treatment (n = 8 in each group). Skeletal muscle GLUT-4 increased, liver PEPCK decreased, pancreatic islet hypertrophy, and β-cell apoptosis in OVX rats treated with GlcN was ameliorated by RLX. The negative effects of GlcN on insulin secretion and cell viability in MIN-6 cells were related to the upregulation of reticulum (ER) stress-associated proteins (C/EBP homologous protein, phospho-extracellular signal-regulated kinase, phospho-c-JunN-terminal kinase), the expression of which was reduced by RLX. Pretreatment with estrogen receptor antagonists reversed the protective effects of RLX. GlcN can induce insulin resistance, β-cell dysfunction, and apoptosis in OVX rats and increase ER stress-related proteins in β-cells, whereas RLX can reverse these adverse effects. The effects of RLX act mainly through estrogen receptor α; therefore, RLX may be a candidate drug for postmenopausal women with OA and OP.

Regular use of glucosamine was significantly related with decreased risk of lung cancer and lung cancer mortality, based on data from this nationwide prospective cohort study.

Glucosamine (GLU) is a natural compound found in cartilage, and supplementation with glucosamine has been shown to improve joint heath and has been linked to reduced mortality rates. GLU is poorly absorbed and may exhibit functional properties in the gut. The purpose of this study was to examine the impact of glucosamine on gastrointestinal function as well as changes in fecal microbiota and metabolome. Healthy males (n = 6) and females (n = 5) (33.4 ± 7.7 years, 174.1 ± 12.0 cm, 76.5 ± 12.9 kg, 25.2 ± 3.1 kg/m2, n = 11) completed two supplementation protocols that each spanned three weeks separated by a washout period that lasted two weeks. In a randomized, double-blind, placebo-controlled, crossover fashion, participants ingested a daily dose of GLU hydrochloride (3000 mg GlucosaGreen®, TSI Group Ltd., Missoula, MT, USA) or maltodextrin placebo. Study participants completed bowel habit and gastrointestinal symptoms questionnaires in addition to providing a stool sample that was analyzed for fecal microbiota and metabolome at baseline and after the completion of each supplementation period. GLU significantly reduced stomach bloating and showed a trend towards reducing constipation and hard stools. Phylogenetic diversity (Faith’s PD) and proportions of Pseudomonadaceae, Peptococcaceae, and Bacillaceae were significantly reduced following GLU consumption. GLU supplementation significantly reduced individual, total branched-chain, and total amino acid excretion, with no glucosamine being detected in any of the fecal samples. GLU had no effect on fecal short-chain fatty acids levels. GLU supplementation provided functional gut health benefits and induced fecal microbiota and metabolome changes.

Hyperlipidemia due to a high-fat diet (HFD) is a risk factor for inducing insulin resistance (IR) and adverse effects onpancreatic β-cells in obesity and type 2 diabetes mellitus. This relationship may be due to activation of the hexosaminebiosynthesis pathway. Administration of exogenous glucosamin …

Glucosamine is an amino monosaccharide with a small molecular weight and has a protective effect against various neurological diseases including multi…

Background Glucosamine hydrochloride, a natural biopolymer present in the daily diet, has various biological activities including antitumour properties and protective effects against pathogens. Early studies showed that daily administration of a derivative of glucosamine induced proliferation of leukemia cells and prolonged overall survival in mice; importantly, no toxicity was associated with the glucosamine treatment. However, the potential mechanism of the antitumour effect is unknown. This study aimed to investigate the inhibitory mechanism and effect of glucosamine on human gastric carcinoma cells in vitro. Methods Gastric carcinoma MKN-45 cells were exposed to 0, 100, 500 and 1000 µg/mL glucosamine hydrochloride for 72 hours, and then the viability and proliferation of gastric carcinoma cells in vitro was measured using the MTT (3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide) assay. Quantitative gene expression of MMP-2 and -3 was determined by real-time polymerase chain reaction. Protein level was analyzed using an enzyme-linked immunosorbent assay (ELISA). Results Glucosamine hydrochloride has a significant inhibitory antitumour effect on MKN-45 cells in vitro. The cell viability of MKN-45 cells treated with different concentrations of glucosamine hydrochloride rose continuously from 24 to 72 hours compared with the untreated control. MKN-45 cells were inhibited by 54% by 500 µg/mL glucosamine hydrochloride and by 85% by 1000 µg/mL glucosamine hydrochloride. Administration of 500 µg/mL glucosamine hydrochloride resulted in a significant decrease in MMP-2 and MMP-3 expression of about 79% and 70%, respectively, in MKN-45 cells. Conclusions In this study, we showed that the antitumour activity of glucosamine hydrochloride significantly suppresses MKN-45 cells in vitro. This effect was shown by inhibitory gene expression of MMP-2 and -3. Acknowledgments This research was financially supported by Zhuhai College of Jilin University.

Background: Osteoarthritis (OA) is a degenerative disease with complex underling mechanisms 1–3. The interactions among several factors make the study of the disease very complex and often lead to different treatment, i.e. surgical or conservative, decisions for subjects clinically and radiographically similar. Recent explorations performed at the body level pointed out that macro-factors, like overweight or gait, can influence the development of the disease 4. The number of related factors is high, and they are very likely to interact with each other. However, the literature lacks randomized and balanced studies to verify such effects of multiple factors 5. Objectives: The aim of this work was to develop a multifactorial analysis to explore whether and how gait functionality and dynamics can be related to treatment decision. Methods: A multifactorial analysis of gait dynamics in OA subjects was developed. 81 OA subjects, graded 2-3 in KL, were selected based on 4 clinical factors: Gender (male – female), Age (60-67 – 68-75), BMI (25–29.9 – 30+) and Treatment (total knee replacement (TKR) – conservative treatment). Gait analysis was performed using 8 cameras BTS Smart-DX 700, 1.5 Mpixels 250 fps and 2 force plates BTS P-6000 500 Hz sampling (BTS S.p.A., Milan, Italy). Helen Hayes marker protocol with medial markers was used for the study. Each volunteer was asked to perform a minimum of 5 valid gait sequences. Functionality and dynamics parameters were measured. Functionality : Velocity of gait and the time needed to perform a gait cycle were computed. Dynamics: The reaction forces and torques at the ankles, knees and hips were computed through inverse dynamic analyses. Analysis of variance was performed for the four factors described among the functionality and dynamics parameters. Results: The multifactorial analysis showed that functionality values are more subjective to the studied factors than the dynamics ones. Functionality seems to be directly related to the clinical treatment. Patients who selected TKR needed more time to make a step, spent more time in double stand position and walked slower (p